Osteoporosis

Women's Health Week (May 14-20, 2023) is an ideal opportunity to review the top research, policy shifts, and potential drug approvals that affect your patient panel.

Denosumab reduced RR of fracture vs alendronate across fracture types, eg, by 36% for hip fracture, by 43% for nonvertebral fractures, and by 30% for vertebral fractures.

Tirzepatide delivers 15.7% weight loss in adults with obesity; remote intervention increases cancer screening in women; women at greater post-MI risk vs men; plus 2 more updates of note.

The updated American College of Physicians osteoporosis treatment guideline is summarized in this topline review for primary care clinicians.

Your daily dose of clinical news you may have missed.

Significant decreases were observed in bone strength and mean and trabecular BMD 12 months after sleeve gastrectomy in patients aged 13 to 25 years, a new study reveals.

Your daily dose of clinical news you may have missed.

Nitrous oxides were found to be the most damaging to bone architecture in the first study to look at the pollution-BMD association in postmenopausal women.

In women with osteoporosis treated with abolaparatide, trabecular bone score increased significantly, reflecting improved bone microarchitecture and strength.

A global prevalence of osteoporosis among persons with T2D of more than 25% calls for greater focus on screening for and managing the bone loss disease in this population.

Among more than 26 000 women, a vegetarian diet was associated with a 33% greater risk of hip fracture vs diets that included fish or meat.

ENDO 2021: Fewer than 1-in-10 older adults with a hip fracture had been prescribed bone-directed treatment in the 6 months prior to the incident, according to research on trends in treatment.

A new study found that post-hip fracture, less than 5% of elderly patients were started on osteoporosis medication despite high risk for recurrent fracture.